NG Therapeutic Antibody Market Examined in New Visiongain Research Report Published at

Share Article

Answers to a number of questions on next-generation antibody therapies can be found in the new research report “Next-Generation Antibody Therapies: Pipeline and Market 2011-2021” provided by Visiongain has been recently published by Market Publishers Ltd.

Market Publishers Ltd

What are the prospects for emerging antibody technologies? Which next-generation antibodies will be the most important to the future of antibody therapeutics? Which technologies will be the game-changers in the antibodies industry? How will the therapeutic antibody market change? Will biosimilar antibodies disrupt or rejuvenate the market?

Answers to all these questions and many more can be found in the new research report “Next-Generation Antibody Therapies: Pipeline and Market 2011-2021” provided by Visiongain has been recently published by Market Publishers Ltd.

Report Details:

Title: Next-Generation Antibody Therapies: Pipeline and Market 2011-2021
Published: November, 2011
Pages: 185
Price: US$ 2,664
The report is a must-have for those needing industry and market analysis for next-generation therapeutic antibody technologies.

Report Scope:

  •     overview of R&D for therapeutic antibody technologies, assessment of pipeline trends in oncology and other areas of medicine;
  •     revenue predictions to 2021 for the overall world market and technological submarkets;
  •     assessment of companies in the antibodies industry, their activities and outlooks;
  •     2010 revenue breakdown for therapeutic antibody markets in the US, Japan, Germany, France, the UK, Spain, Italy, China and India;
  •     analysis of competition and opportunities from 2011 onwards;
  •     analysis of what will stimulate and restrain the industry and market from 2011;
  •     opportunities and challenges for established and emerging companies;
  •     interviews with authorities on the therapeutic antibodies industry.

Report Contents:

1. Executive Summary

1.1 Next-Generation Antibodies: Market Overview
1.2 Contents of this Report
1.3 Research and Analysis Methods

2. Antibody Therapeutics: Scientific and Clinical Overview, 2011

2.1 Antibodies and the Immune System
2.2 How Antibodies Work
2.3 Structure of Antibodies
2.3.1 The Fab Region
2.3.2 The Fc Region
2.4 Brief History of Antibody Discovery and Innovation
2.5 Types of Therapeutic Antibody
2.5.1 Polyclonal Antibodies
2.5.2 Monoclonal Antibodies
2.5.3 Murine Monoclonal Antibodies
2.5.4 Chimeric and Humanised Monoclonal Antibodies
2.5.5 Fully Human Monoclonal Antibodies
2.5.6 Fab Fragments
2.5.7 Fusion Proteins
2.6 Currently-Approved Monoclonal Antibody Therapies
2.7 Potential Next-Generation Antibody Therapeutics

3. Antibody Therapeutics: Pipeline and Market Overview, 2011-2021

3.1 Antibody Therapeutics: Market Forecast, 2011-2021
3.3.1 Next-Generation Products will Increase Their Market Share
3.2 Antibody Therapeutics Market, 2011-2021: Pipeline Overview
3.3 Leading Players in the Antibody Field, 2011-2021
3.4 Leading National Antibody Markets
3.5 Next-Generation Therapeutic Antibody Technologies: SWOT Analysis
3.5.1 Strengths
3.5.2 Weaknesses
3.5.3 Opportunities
3.5.4 Threats

4. Engineered Antibodies Market, 2011-2021

4.1 Engineered Antibodies: Market Forecast, 2011-2021
4.2 Engineered Antibodies: Overview of the Field in 2011
4.2.1 The Major Fc Engineering Platforms
4.2.2 New Expression Systems, Purification Systems, and Other Production Improvements
4.3 Engineered Antibodies: Products and Pipeline, 2011
4.3.1 Afutuzumab and Other GlycoMAB-Engineered Products (Roche)
4.3.2 KW0761 and Other Potelligent Products (Kyowa Hakko Kirin)
4.3.3 XmAb (Xencor)
4.3.4 MGAH22 and MGA271 (Macrogenics)
4.3.5 AME-133v (Mentrik Biotech)
4.3.6 LFB-R603 (LFB)
4.4 Engineered Antibodies: SWOT Analysis
4.4.1 Strengths
4.4.2 Weaknesses
4.4.3 Opportunities
4.4.4 Threats

5. Antibody-Drug Conjugates Market 2011-2021

5.1 Antibody-Drug Conjugates: Market Forecast, 2011-2021
5.2 Antibody-Drug Conjugates: Overview of the Field in 2011
5.2.1 Existing Antibody-Drug Conjugate Products
5.3 Antibody-Drug Conjugates Pipeline, 2011
5.3.1 Trastuzumab DM-1(Roche)
5.3.2 Roche's Other ADC Collaborations (Roche/ Seattle Genetics)
5.3.3 CMC-544 (Pfizer)
5.3.4 IMGN901 (ImmunoGen)
5.3.5 BT-062 (Biotest)
5.3.6 CDX-011 and CDX-014 (Celldex)
5.3.7 BIIB015 (Biogen Idec)
5.3.8 SAR3419 and SAR566658 (Sanofi)
5.3.9 hLL1-Dox and Others (Immunomedics)
5.3.10 MDX-1203 (Bristol-Myers Squibb)
5.3.11 SGN-75 (Seattle Genetics)
5.3.12 AGS-5ME and Others (Astellas/ Agensys/ Seattle Genetics)
5.3.13 BAY 79-4620 and BAY 94-9343 (Bayer Schering/ Seattle Genetics / ImmunoGen)
5.3.14 PSMA ADC (Progenics Pharmaceuticals/ Seattle Genetics)
5.3.15 HuMax ADCs (Genmab/ Seattle Genetics)
5.3.16 Antibody-Radioisotope and Other Immunoconjugate Formats (Various)
5.4 Antibody-Drug Conjugates: SWOT Analysis
5.4.1 Strengths
5.4.2 Weaknesses
5.4.3 Opportunities
5.4.4 Threats

6. Bispecific Antibodies Market 2011-2021

6.1 Bispecific Antibodies: Market Forecast, 2011-2021
6.2 Bispecific Antibodies: Overview of the Field in 2011
6.3 Bispecific Antibodies: Pipeline, 2011

More new market research reports by the publisher can be found at Visiongain page.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tanya Rezler
Visit website